quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:15:56·35d
SECFiling
Biofrontera Inc. logo

SEC Form 10-K filed by Biofrontera Inc.

BFRI· Biofrontera Inc.
Health Care
Full content unavailable. See the original source below.
Original source

Companies

  • BFRI
    Biofrontera Inc.
    Health Care

Recent analyst ratings

  • Dec 15UpdateBenchmark$11.00
  • Nov 24UpdateRoth Capital$20.00

Related

  • SEC35d
    Biofrontera Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
  • PR35d
    Biofrontera Inc. Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
  • PR45d
    Biofrontera Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call on March 19, 2026
  • SEC45d
    Biofrontera Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
  • PR45d
    Biofrontera Inc. Reports Positive Phase 2b Results Supporting Further Development of Ameluz® Photodynamic Therapy for moderate to severe Acne Vulgaris
  • INSIDER48d
    SEC Form 4 filed by Director Weber Kevin Daniel
  • INSIDER48d
    CEO & Chairman Luebbert Hermann converted options into 137,500 shares, increasing direct ownership by 90% to 290,211 units (SEC Form 4)
  • INSIDER48d
    Chief Financial Officer Leffler Eugene Frederick converted options into 87,500 shares, increasing direct ownership by 100% to 175,000 units (SEC Form 4)
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022